What is InteRNA Technologies?
InteRNA Technologies operates at the intersection of molecular biology and clinical drug development. The company specializes in the discovery and development of microRNA-based therapeutics, which are designed to modulate gene expression to treat various pathologies, with a primary emphasis on oncology. By targeting the fundamental processes of disease initiation, the firm aims to provide novel treatment modalities that offer superior efficacy compared to traditional small-molecule or antibody-based approaches. Based in the Netherlands, the company leverages a proprietary platform to identify and validate miRNA candidates, effectively bridging the gap between early-stage research and clinical application.
How much funding has InteRNA Technologies raised?
InteRNA Technologies has raised a total of $32.9M across 2 funding rounds:
Series A
$10.5M
Series B
$22.4M
Series A (2015): $10.5M with participation from INKEF Capital and Aglaia Biomedical Ventures B.V.
Series B (2021): $22.4M led by waterman-ventures.com, Oost NL, AurorA Science, and Aglaia Oncology Funds
Key Investors in InteRNA Technologies
Aglaia Biomedical Ventures B.V.
Aglaia Oncology Funds is an oncology specialist investor focused on selecting and maturing early-stage breakthrough inventions that can transform cancer prevention, diagnosis, and therapy.
INKEF Capital
INKEF Capital is an Amsterdam-based venture capital firm that focuses on long-term collaboration and active support of innovative technology and healthcare companies.
Oost NL
Oost NL is a regional development agency that invests in innovative companies in the East Netherlands to stimulate economic growth and technological advancement.
What's next for InteRNA Technologies?
With the recent capital injection, InteRNA Technologies is well-positioned to accelerate its clinical development programs and expand its research capabilities. The strategic focus will likely center on advancing its lead candidates through rigorous clinical trials while simultaneously de-risking its pipeline for potential future licensing agreements or strategic partnerships with larger pharmaceutical entities. As the biotech sector continues to prioritize precision medicine, InteRNA's focus on miRNA therapeutics provides a distinct competitive advantage. The company's ability to maintain a lean, high-impact operational model while navigating the complexities of drug development will be essential as it moves toward subsequent milestones in its growth trajectory.
See full InteRNA Technologies company page
